Combination treatments for myelofibrosis in jak inhibitor-naive patients: evidence, rationale, and clinical direction

Beyond higher rates of spleen and symptom responses, emerging signals suggest combination may deliver reductions in mutant variant allele frequency and improvements in bone marrow fibrosis, supporting a potential shift toward disease modification. However, important gaps remain regarding long-term outcomes, safety, and optimal patient selection, which could range from all, to high risk to those planned for transplant, and these signals require confirmation with longer follow-up and standardized assessment methods including those for toxicity to define the role of combination therapy in the evolving management of MF.